| Autor: |
Tural, Deniz, Ölmez, Ömer Fatih, Sümbül, Ahmet Taner, Özhan, Nail, Akar, Ebru, Çakar, Bilge, Köstek, Osman, Ekenel, Mahmut, Erman, Mustafa, Coşkun, Hasan Şenol, Selçukbiricik, Fatih, Keskin, Özge, Paksoy, Fatma, Oruç, Korkmaz, Bayram, Süleyman Nuri, Yılmaz, Uğur, Bilgetekin, İrem, Yıldız, Birol, Şendur, Mehmet Ali Nahit, Artaç, Macide |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Popis: |
Background: In the current study, we evaluated pretreatment prognostic factors foroverall survival (OS) in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy in the Expanded-Access Program ofatezolizumab.Methods: In this study, we present the retrospective analysis of 113 patients withurothelial cancer treated with ATZ after progression on first-line chemotherapy.Eligible patients included metastatic urothelial carcinoma patients treated with at leastone course of ATZ. Univariate analysis was used to identify clinical and laboratoryfactors that significantly impact OS. Variables were retained for multivariate analysis ifthey had a statistical relationship with OS (P˂0.1) and were then included the finalmodel if P˂0.05.Results: In univariate analysis, primary tumour location in the upper tract, increasedabsolute neutrophil count (ANC), increased absolute lymphocyte count, neutrophil-tolymphocyte ratio (NLR)>3, liver metastases, baseline creatinine clearance (GFR) < 60ml/min, Eastern Cooperative Oncology Group (ECOG) performance status (1) andhemoglobin3 (HR¼ 0.474; 95% CI 0.234-0.962; P ¼0.039) and GFR 3 andGFR |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
